QR was founded in 2005, as a domestic formulation company, and we produce API for our own formulation as well. We are the sole manufacturer of L-Ornithine-L-Aspartate formulations and API in China, which have been ranked No. 1 sales among liver-protective products in China throughout 2007-2012. Fasudil Mesylate is our 2nd approved product in China with API produced by ourselves. We have R&D center in Shanghai and manufacturing plants in Wuhan. We are expanding new facilities now, with new API plant to be finished by end of 2012, and expanded new formulation facility by mid of 2013.
QR is a young company with vitality, vertically integrated with R&D, manufacturing, marketing and sales. We were Chinese business focused in the past 7 years, but we are striving to be a global player in the near future when our new facility is completed. We have the plan of filing DMF for 3-4 APIs in 2013, and we have the attention to get our API site inspected by FDA or EMEA.

QR is looking for partners in licensing, co-development, CMO, marketing and distribution.